Peregrine’s Brain Cancer Agent Shows Promise, Shares Up

Peregrine Pharmaceuticals Inc said its experimental brain cancer agent Cotara appeared well tolerated and showed encouraging signs of efficacy in a mid-stage trial, sending its shares up 21 percent in pre-market trade.
Forbes